Justus S Israel, Laura-Maria Marcelin, Sherif Mehralivand, Jana Scholze, Jörg Hofmann, Matthias B Stope, Martin Puhr, Christian Thomas, Holger H H Erb
{"title":"雄激素诱导的翻译在调节雄激素受体活性方面的影响。","authors":"Justus S Israel, Laura-Maria Marcelin, Sherif Mehralivand, Jana Scholze, Jörg Hofmann, Matthias B Stope, Martin Puhr, Christian Thomas, Holger H H Erb","doi":"10.1186/s13062-024-00550-6","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Dysregulated androgen receptor (AR) activity is central to various diseases, particularly prostate cancer (PCa), in which it drives tumour initiation and progression. Consequently, antagonising AR activity via anti-androgens is an indispensable treatment option for metastatic PCa. However, despite initial tumour remission, drug resistance occurs. Therefore, the AR signalling pathway has been intensively investigated. However, the role of AR protein stability in AR signalling and therapy resistance has not yet been deciphered. Therefore, this study aimed to investigate the role of AR protein changes in transactivity and assess its mechanism as a possible target in PCa.</p><p><strong>Methods: </strong>LNCaP, C4-2, and 22Rv1 cells were treated with R1881, enzalutamide, cycloheximide, and Rocaglamide. Mass spectrometry analyses were performed on LNCaP cells to identify the pathways enriched by the treatments. Western blotting was performed to investigate AR protein levels and localisation changes. Changes in AR transactivity were determined by qPCR.</p><p><strong>Results: </strong>Mass spectrometry analyses were performed on LNCaP cells to decipher the molecular mechanisms underlying androgen- and antiandrogen-induced alterations in the AR protein. Pathway analysis revealed the enrichment of proteins involved in different pathways that regulate translation. Translational and proteasome inhibitor experiments revealed that these AR protein changes were attributable to modifications in translational activity. Interestingly, the effects on AR protein levels in castration-resistant PCa (CRPC) cells C4-2 or enzalutamide-resistant cells 22Rv1 were less prominent and non-existent. This outcome was similarly observed in the alteration of AR transactivation, which was suppressed in hormone-sensitive prostate cancer (HSPC) LNCaP cells by translational inhibition, akin to the effect of enzalutamide. In contrast, treatment-resistant cell lines showed only a slight change in AR transcription.</p><p><strong>Conclusion: </strong>This study suggests that in HSPC, AR activation triggers a signalling cascade that increases AR protein levels by enhancing its translation rate, thereby amplifying AR activity. However, this mechanism appears to be dysregulated in castration-resistant PCa cells.</p>","PeriodicalId":9164,"journal":{"name":"Biology Direct","volume":"19 1","pages":"111"},"PeriodicalIF":5.7000,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11555926/pdf/","citationCount":"0","resultStr":"{\"title\":\"The impact of androgen-induced translation in modulating androgen receptor activity.\",\"authors\":\"Justus S Israel, Laura-Maria Marcelin, Sherif Mehralivand, Jana Scholze, Jörg Hofmann, Matthias B Stope, Martin Puhr, Christian Thomas, Holger H H Erb\",\"doi\":\"10.1186/s13062-024-00550-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Dysregulated androgen receptor (AR) activity is central to various diseases, particularly prostate cancer (PCa), in which it drives tumour initiation and progression. Consequently, antagonising AR activity via anti-androgens is an indispensable treatment option for metastatic PCa. However, despite initial tumour remission, drug resistance occurs. Therefore, the AR signalling pathway has been intensively investigated. However, the role of AR protein stability in AR signalling and therapy resistance has not yet been deciphered. Therefore, this study aimed to investigate the role of AR protein changes in transactivity and assess its mechanism as a possible target in PCa.</p><p><strong>Methods: </strong>LNCaP, C4-2, and 22Rv1 cells were treated with R1881, enzalutamide, cycloheximide, and Rocaglamide. Mass spectrometry analyses were performed on LNCaP cells to identify the pathways enriched by the treatments. Western blotting was performed to investigate AR protein levels and localisation changes. Changes in AR transactivity were determined by qPCR.</p><p><strong>Results: </strong>Mass spectrometry analyses were performed on LNCaP cells to decipher the molecular mechanisms underlying androgen- and antiandrogen-induced alterations in the AR protein. Pathway analysis revealed the enrichment of proteins involved in different pathways that regulate translation. Translational and proteasome inhibitor experiments revealed that these AR protein changes were attributable to modifications in translational activity. Interestingly, the effects on AR protein levels in castration-resistant PCa (CRPC) cells C4-2 or enzalutamide-resistant cells 22Rv1 were less prominent and non-existent. This outcome was similarly observed in the alteration of AR transactivation, which was suppressed in hormone-sensitive prostate cancer (HSPC) LNCaP cells by translational inhibition, akin to the effect of enzalutamide. In contrast, treatment-resistant cell lines showed only a slight change in AR transcription.</p><p><strong>Conclusion: </strong>This study suggests that in HSPC, AR activation triggers a signalling cascade that increases AR protein levels by enhancing its translation rate, thereby amplifying AR activity. However, this mechanism appears to be dysregulated in castration-resistant PCa cells.</p>\",\"PeriodicalId\":9164,\"journal\":{\"name\":\"Biology Direct\",\"volume\":\"19 1\",\"pages\":\"111\"},\"PeriodicalIF\":5.7000,\"publicationDate\":\"2024-11-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11555926/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biology Direct\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://doi.org/10.1186/s13062-024-00550-6\",\"RegionNum\":2,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biology Direct","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1186/s13062-024-00550-6","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
导言:雄激素受体(AR)活性失调是各种疾病,尤其是前列腺癌(PCa)的核心问题,它是肿瘤发生和发展的驱动力。因此,通过抗雄激素拮抗 AR 活性是治疗转移性 PCa 不可或缺的方法。然而,尽管最初肿瘤有所缓解,但仍会出现耐药性。因此,人们对 AR 信号通路进行了深入研究。然而,AR蛋白的稳定性在AR信号传导和耐药性中的作用尚未被揭示。因此,本研究旨在调查AR蛋白变化在转录中的作用,并评估其作为PCa可能靶点的机制:方法:用 R1881、恩扎鲁胺、环己亚胺和 Rocaglamide 处理 LNCaP、C4-2 和 22Rv1 细胞。对 LNCaP 细胞进行质谱分析,以确定处理所富集的通路。对 LNCaP 细胞进行了质谱分析,以确定处理所富集的通路。通过 qPCR 确定 AR 转录活性的变化:对LNCaP细胞进行了质谱分析,以破译雄激素和抗雄激素诱导的AR蛋白变化的分子机制。通路分析表明,参与调节翻译的不同通路的蛋白质富集。翻译和蛋白酶体抑制剂实验显示,这些 AR 蛋白的变化可归因于翻译活性的改变。有趣的是,对阉割耐药 PCa(CRPC)细胞 C4-2 或恩杂鲁胺耐药细胞 22Rv1 中 AR 蛋白水平的影响并不明显,甚至不存在。在激素敏感性前列腺癌(HSPC)LNCaP 细胞中,通过翻译抑制作用抑制了 AR 的转录活化,这与恩杂鲁胺的作用类似。相比之下,耐药细胞系的AR转录仅有轻微变化:这项研究表明,在HSPC中,AR激活会触发一个信号级联,通过提高AR的翻译率来增加AR蛋白水平,从而放大AR的活性。结论:这项研究表明,在HSPC中,AR激活会触发信号级联,通过提高AR的翻译率来增加AR蛋白水平,从而增强AR的活性。
The impact of androgen-induced translation in modulating androgen receptor activity.
Introduction: Dysregulated androgen receptor (AR) activity is central to various diseases, particularly prostate cancer (PCa), in which it drives tumour initiation and progression. Consequently, antagonising AR activity via anti-androgens is an indispensable treatment option for metastatic PCa. However, despite initial tumour remission, drug resistance occurs. Therefore, the AR signalling pathway has been intensively investigated. However, the role of AR protein stability in AR signalling and therapy resistance has not yet been deciphered. Therefore, this study aimed to investigate the role of AR protein changes in transactivity and assess its mechanism as a possible target in PCa.
Methods: LNCaP, C4-2, and 22Rv1 cells were treated with R1881, enzalutamide, cycloheximide, and Rocaglamide. Mass spectrometry analyses were performed on LNCaP cells to identify the pathways enriched by the treatments. Western blotting was performed to investigate AR protein levels and localisation changes. Changes in AR transactivity were determined by qPCR.
Results: Mass spectrometry analyses were performed on LNCaP cells to decipher the molecular mechanisms underlying androgen- and antiandrogen-induced alterations in the AR protein. Pathway analysis revealed the enrichment of proteins involved in different pathways that regulate translation. Translational and proteasome inhibitor experiments revealed that these AR protein changes were attributable to modifications in translational activity. Interestingly, the effects on AR protein levels in castration-resistant PCa (CRPC) cells C4-2 or enzalutamide-resistant cells 22Rv1 were less prominent and non-existent. This outcome was similarly observed in the alteration of AR transactivation, which was suppressed in hormone-sensitive prostate cancer (HSPC) LNCaP cells by translational inhibition, akin to the effect of enzalutamide. In contrast, treatment-resistant cell lines showed only a slight change in AR transcription.
Conclusion: This study suggests that in HSPC, AR activation triggers a signalling cascade that increases AR protein levels by enhancing its translation rate, thereby amplifying AR activity. However, this mechanism appears to be dysregulated in castration-resistant PCa cells.
期刊介绍:
Biology Direct serves the life science research community as an open access, peer-reviewed online journal, providing authors and readers with an alternative to the traditional model of peer review. Biology Direct considers original research articles, hypotheses, comments, discovery notes and reviews in subject areas currently identified as those most conducive to the open review approach, primarily those with a significant non-experimental component.